ATE545422T1 - Beta-glycolipide als immunomodulatoren - Google Patents

Beta-glycolipide als immunomodulatoren

Info

Publication number: ATE545422T1
Authority: AT; Austria
Prior art keywords: ceramide; immunomodulators; relates; lactosyl; glycolipids
Prior art date: 2005-11-24

Application number

AT06809778T

Other languages

English (en)

Inventor

Yaron Ilan

Original Assignee

Enzo Biochem Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-24

Filing date

2006-10-23

Publication date

2012-03-15

2006-10-23 Application filed by Enzo Biochem Inc filed Critical Enzo Biochem Inc

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE545422T1 publication Critical patent/ATE545422T1/de

Links

239000002955 immunomodulating agent Substances 0.000 title abstract 2
229940121354 immunomodulator Drugs 0.000 title abstract 2
239000000203 mixture Substances 0.000 abstract 3
QYWVASPEUXEHSY-NNRNTGNWSA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-(docosanoyl)sphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QYWVASPEUXEHSY-NNRNTGNWSA-N 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
OTGQIQQTPXJQRG-UHFFFAOYSA-N N-(octadecanoyl)ethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCO OTGQIQQTPXJQRG-UHFFFAOYSA-N 0.000 abstract 1
YDNKGFDKKRUKPY-UHFFFAOYSA-N N-palmitoyldihydro-sphingosine Natural products CCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-UHFFFAOYSA-N 0.000 abstract 1
210000000447 Th1 cell Anatomy 0.000 abstract 1
210000004241 Th2 cell Anatomy 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
POQRWMRXUOPCLD-HIIAJUEOSA-N beta-D-galactosyl-N-(tetracosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O POQRWMRXUOPCLD-HIIAJUEOSA-N 0.000 abstract 1
YIGARKIIFOHVPF-CNUVFPMCSA-N beta-D-glucosyl-N-(docosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YIGARKIIFOHVPF-CNUVFPMCSA-N 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Oncology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Child & Adolescent Psychology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)

AT06809778T 2005-11-24 2006-10-23 Beta-glycolipide als immunomodulatoren ATE545422T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL172175A IL172175A0 (en)	2005-11-24	2005-11-24	Beta glycolipids as immuno-modulators
PCT/IL2006/001217 WO2007060652A1 (en)	2005-11-24	2006-10-23	Beta glycolipids as immuno-modulators

Publications (1)

Publication Number	Publication Date
ATE545422T1 true ATE545422T1 (de)	2012-03-15

Family

ID=37813589

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06809778T ATE545422T1 (de)	2005-11-24	2006-10-23	Beta-glycolipide als immunomodulatoren

Country Status (8)

Country	Link
US (1)	US7897580B2 (de)
EP (1)	EP1957083B1 (de)
JP (1)	JP2009517378A (de)
CN (1)	CN101384268A (de)
AT (1)	ATE545422T1 (de)
CA (1)	CA2630935C (de)
IL (3)	IL172175A0 (de)
WO (1)	WO2007060652A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL142802A (en) *	2000-04-27	2015-01-29	Enzo Therapeutics Inc	Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma
WO2005032462A2 (en)	2003-02-27	2005-04-14	Enzo Therapeutics, Inc.	Glucocerebroside treatment of disease
US9717754B2 (en)	2003-02-27	2017-08-01	Enzo Therapeutics, Inc.	Glucocerebroside treatment of disease
CN101123986A (zh) *	2003-09-30	2008-02-13	恩佐治疗学股份有限公司	葡糖脑苷脂治疗疾病
US7883703B2 (en) *	2003-11-14	2011-02-08	The Brigham And Women's Hospital, Inc.	Methods of modulating immunity
IL178821A0 (en) *	2006-05-25	2007-07-04	Ilan Yaron	Direct and indirect modulation of composition and structure of cell membrane by ??-glycolipids
IL187959A0 (en) *	2007-12-06	2008-12-29	Haim Lotan	Beta glycolipids for the treatment of calcification related degenerative disorders
US20110200617A1 (en) *	2008-01-18	2011-08-18	Yaron Ilan	Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
NZ571856A (en) *	2008-10-09	2011-02-25	Fonterra Corporate Res And Dev Ltd	Use of a phospholipid and ganglioside composition for the treatment or prevention of gout
NZ598668A (en)	2009-09-01	2014-07-25	Lz Therapeutics Inc	Methods for extraction and purification of gangliosides
WO2011146804A2 (en) *	2010-05-20	2011-11-24	Lazarus Therapeutics, Inc.	Gm3 ganglioside replacement therapy
JP5967754B2 (ja) *	2011-05-02	2016-08-10	興人ライフサイエンス株式会社	酵母エキス抽出残渣の利用法
WO2013049220A1 (en) *	2011-09-30	2013-04-04	University Of Southern California	Novel vaccination strategies or therapeutic treatment for influenza virus
MX2014008797A (es)	2012-01-20	2014-10-30	Garnet Biotherapeutics Inc	Metodos para la produccion gangliosidos.
US20170035791A1 (en) *	2014-04-14	2017-02-09	Natural Shield Israel 2016 Ltd	Combination of beta-glucosylceramide and polyethoxylated castor oil and other adjuvants for controling blood sugar levels, immunoprotection and hepatoprotection
CN104383528B (zh) *	2014-10-24	2016-08-24	江苏省农业科学院	猪流行性腹泻灭活疫苗及其制备方法
WO2018002937A1 (en) *	2016-06-29	2018-01-04	Hadasit Medical Research Services & Development Limited	Combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, compositions and uses thereof in the treatment of disorders associated with protein misfolding and protein aggregations
CN115028671B (zh) *	2021-03-03	2026-05-19	东莞市东阳光冬虫夏草研发有限公司	一种冬虫夏草提取物、制备方法及其用途
CN115010775B (zh) *	2021-03-03	2026-07-14	东莞市东阳光冬虫夏草研发有限公司	一类脑苷脂化合物作为免疫抑制剂的用途
US20260041622A1 (en) *	2022-08-05	2026-02-12	Carbocode S.A.	Reduction of Signs of Skin Aging

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0300960B1 (de) *	1987-06-26	1994-12-21	Solco Basel AG	Neue pharmazeutische Präparate sowie neue Lactosylverbindungen und ihre Herstellung
US5686426A (en)	1994-11-17	1997-11-11	Bristol-Myers Squibb Company	Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
FR2728707A1 (fr) *	1994-12-22	1996-06-28	Alcatel Postal Automation Syst	Dispositif de lecture d'un code a barres pour une installation de tri postal
CA2316041A1 (en) *	1997-12-30	1999-07-08	Pam Fredman	Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
AUPP675898A0 (en)	1998-10-27	1998-11-19	Walter And Eliza Hall Institute Of Medical Research, The	A method of activating t cells and agents useful for same
IL140537A0 (en) *	2000-12-25	2002-02-10	Hadasit Med Res Service	Educated nk t cells and their uses in the treatment of immune-related disorders
AU2002327338A1 (en) *	2001-07-25	2003-02-17	New York University	Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US20040171522A1 (en)	2003-02-27	2004-09-02	Yaron Ilan	Regulation of immune responses by manipulation of intermediary metabolite levels
WO2005032462A2 (en)	2003-02-27	2005-04-14	Enzo Therapeutics, Inc.	Glucocerebroside treatment of disease
EP1653977A2 (de)	2003-07-17	2006-05-10	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Behandlung von erkrankungen im zusammenhang mit natürlichen killer-t-zellen

2005
- 2005-11-24 IL IL172175A patent/IL172175A0/en unknown
- 2005-11-25 US US11/287,502 patent/US7897580B2/en active Active
2006
- 2006-10-23 WO PCT/IL2006/001217 patent/WO2007060652A1/en not_active Ceased
- 2006-10-23 EP EP06809778A patent/EP1957083B1/de active Active
- 2006-10-23 CN CNA2006800517473A patent/CN101384268A/zh active Pending
- 2006-10-23 AT AT06809778T patent/ATE545422T1/de active
- 2006-10-23 JP JP2008541906A patent/JP2009517378A/ja active Pending
- 2006-10-23 CA CA2630935A patent/CA2630935C/en active Active
2008
- 2008-05-22 IL IL191627A patent/IL191627A/en active IP Right Grant
2017
- 2017-02-27 IL IL250832A patent/IL250832B/en active IP Right Grant

Also Published As

Publication number	Publication date
EP1957083A1 (de)	2008-08-20
IL191627A0 (en)	2008-12-29
EP1957083B1 (de)	2012-02-15
JP2009517378A (ja)	2009-04-30
IL250832A0 (en)	2017-04-30
US7897580B2 (en)	2011-03-01
WO2007060652A1 (en)	2007-05-31
CN101384268A (zh)	2009-03-11
IL191627A (en)	2017-03-30
CA2630935C (en)	2014-08-12
CA2630935A1 (en)	2007-05-31
US20070117778A1 (en)	2007-05-24
IL172175A0 (en)	2011-08-01
IL250832B (en)	2019-03-31

Publication	Publication Date	Title
IL250832B (en)	2019-03-31	A mixture of beta-glycosylceramide and beta-lactosylceramide for use in the treatment of colitis
HUS2100051I1 (hu)	2021-12-28	Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
UA101493C2 (ru)	2013-04-10	Производные азетидина и циклобутана как ингибиторы jak
MXPA06014510A (es)	2007-09-19	Composiciones y metodos para tratar trastornos inflamatorios.
MX2011006959A (es)	2011-12-06	Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
PH12012501323A1 (en)	2014-12-17	Substituted imidazopyridinyl-aminopyridine compounds
MX2007004551A (es)	2007-05-23	Compuestos tiadiazol y metodos de uso.
PH12015502575B1 (en)	2017-04-24	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MX2009009283A (es)	2009-11-18	Anticuerpos anti-interleuquina -23r de ingenieria.
MX2009009079A (es)	2009-08-31	Anticuerpos anti-il-23p19 de ingenieria.
EA201170005A1 (ru)	2011-08-30	Диаминопиридиновые, пиримидиновые и пиридазиновые модуляторы гистаминового рецептора h
UA102065C2 (xx)	2013-06-10	Заміщені 4-арил-1,4-дигідро-1,6-нафтиридинаміди і їх застосування$замещенные 4-арил-1,4-дигидро-1,6-нафтиридинамиды и их применение
WO2011082273A3 (en)	2011-10-20	Substituted pyrrolo-aminopyrimidine compounds
MX370721B (es)	2019-12-20	Compuestos y composiciones novedosas para atacar las células madre del cáncer.
IL187382A0 (en)	2008-02-09	Bicyclic derivatives as modulators of ion channels
ZA200702322B (en)	2009-11-25	Compositions and methods for the diagnosis and treatment of tumor
WO2008094254A3 (en)	2008-12-11	Methods and compositions for the treatment of cancer or other diseases
WO2011082267A3 (en)	2011-11-24	Substituted triazolo-pyrazine compounds
EA200970765A1 (ru)	2009-12-30	2-аминопиримидиновые модуляторы рецептора hгистамина
EA201490911A1 (ru)	2014-09-30	Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина
ZA200702375B (en)	2009-03-25	Quinazolines useful as modulators of ion channels
MX2022016342A (es)	2023-01-24	Union de anticuerpos multiespecificos a bcma.
SG162747A1 (en)	2010-07-29	Erythropoietin receptor peptide formulations and uses
WO2011082268A3 (en)	2011-10-20	Substituted naphthalenyl-pyrimidine compounds
MXPA05003718A (es)	2005-09-30	Compuestos x-nitro, sus composiciones farmaceuticas y sus usos.